Introduction 1
Many neurophysiological outputs, such as heart rate and motor activity, exhibit fractal or self- exponent α in the two regions (i.e., α 1 at < 90 minutes, and α 2 from 2 hours up to 10 hours), 7 respectively, omitting the transitional region of time-scales between 1.5 and 2 hours (Fig. 1) . In 8 other words, we assessed FR degradation from the changes in the scaling of fluctuation 9 amplitude F(n) that can be quantified by the two scaling exponents (α 1 and α 2 ). To ensure reliable 10 estimation of F(n) at a time scale n, at least six segments without gaps of size n are required. 11
Otherwise F(n) at and beyond that time scale will not be estimated. The time scale n sequence 12 starts from 1.5 min (i.e., 6 data points with epoch length = 15 sec) and ends at a maximal time 13 scale that was determined by the length and gaps of the signals. The selected time scales were 14 uniformly distributed with 8 points in each log 2 interval. For all activity recordings, the maximal 15 time scale was greater than 90 minutes such that there was no missing data for α 1 . To obtain 16 reliable α 2 , we also required a reliable estimation of F(n) between time scales n = 2 hours to at 17 least 8 hours. In thirteen recordings, the maximal time scale was < 8 hours such that α 2 could not 18 be obtained. 19 20
Statistical analysis 21
To examine how FR changes longitudinally and how this longitudinal change varies with the 22 progression of Alzheimer's disease, we performed linear mixed-effects models with 2 change 23 points anchored at the diagnoses of MCI and Alzheimer's dementia. In these models, the scaling 1 exponents (i.e., α 1 and α 2 ) were the longitudinal outcomes, and time in years since baseline was a 2 predictor. The first change point was set at MCI diagnosis and time in years since this change 3 point was included to estimate additional changes in FR after MCI diagnosis. The second change 4 point was set at the diagnosis of Alzheimer's dementia and time in years since this change point 5 was included to estimate additional changes after the diagnosis of Alzheimer's dementia. These 6 analyses were performed using MATLAB Statistics and Machine Learning Toolbox (Ver. 7
R2018a, The MathWorks Inc., Natick, MA, USA). Next, we examined whether the longitudinal 8 change in FR is correlated with the change in cognition. Bivariate linear mixed models were used 9 to examine the simultaneous changes in the scaling exponent α 1 and global cognition, and 10 separately, in the scaling exponent α 2 and global cognition (Buchman et al., 2014). The 11 correlations between the changes in the scaling exponents and cognition are captured by the 12 covariance structure of the random effects, such that a significant and positive/negative 13 covariance between the random slopes of the scaling exponents and cognition would indicate 14 that both FR and cognition change in the same/opposite direction over time. These analyses were 15 done using SAS/STAT software (Ver. 9.4 of the SAS System for Linux, SAS Institute Inc., Cary, 16
Figure 2 summarizes the numbers of participants available in each follow up year by the time of 1 analysis and disaggregated data for each category at baseline as well as converters (i.e., NCI to 2 MCI, MCI to Alzheimer's dementia) during follow up assessments. The demographic and 3 actigraphic characteristics of all participants are summarized in Table 1 . At baseline, α 1 ranges 4 from 0.63 to 1.21 and α 2 ranges from 0.51 to 1.32, suggesting positive multiscale correlations (α 5 > 0.5) in motor activity in both time scale regions and in all participants. Baseline α 1 is weakly 6 correlated with baseline α 2 (Pearson r = 0.07, p = 0.03). Both baseline α 1 and baseline α 2 are 7 negatively correlated with age (α 1 : r = -0.09, p = 0.004; α 2 : r = -0.15, p < 0.0001). Neither 8 baseline α 1 nor baseline α 2 is correlated with years of education (both p's > 0.1). There are no sex 9 differences in either baseline α 1 or baseline α 2 (both p's > 0.2). 10
11
Participants had an average of 5 repeated actigraphy assessments (range 2-13) ( Fig. 2A) . For 12 those who were NCI at baseline, 339 developed MCI (Fig 2B; Table 1 ) at averagely ~3.4 years 13 after baseline. For those who developed Alzheimer's dementia during follow up assessments, the 14 average time interval between MCI onset and the diagnosis of Alzheimer's dementia was about 4 15 years, and they were further followed on average ~2.5 years after the diagnosis of Alzheimer's 16 dementia. 17 During the NCI stage, both α 1 and α 2 decreased over time with an annual decline of 0.002 ± 21 0.0005 (mean ± SE unless otherwise indicated) for α 1 (p < 0.0001) and of 0.006 ± 0.0007 for α 2 22 (p < 0.0001) (Table 2; Fig. 3 ), suggesting that activity fluctuations in both time scale regions 23 became more random with aging. These degradations did not differ between females and males 1 or by years of education (all p's > 0.1) (Tables 2) except that higher years of education was 2 associated with slower decline rate in α 2 (p = 0.045). The decline in α 1 was faster in older 3 individuals (p < 0.0001) ( Table 2) . On the other hand, we did not observe a significant 4 association of baseline age with decline rate in α 2 (p = 0.5) ( Table 2) . 5 6 After MCI diagnosis, α 1 declined much faster and the decline rate was increased by 150% 7 (Estimate of increase: 0.003 ± 0.001; p = 0.0003) (Table 3) . Similarly, α 2 also declined faster 8 after MCI diagnosis, i.e., the rate increased by ~133% after the diagnosis (Estimate of increase: 9 0.008 ± 0.001 p < 0.0001) (Table 2; Fig. 3 ). 10
After the clinical onset of Alzheimer's dementia, the declines in α 1 and α 2 were further 12 accelerated with an increase of 0.017 ± 0.003 for α 1 (4.4 times of the rate at MCI, p < 0.0001) 13
and an increase of 0.016 ± 0.005 for α 2 (2.1 times of the rate at MCI, p = 0.0005), respectively 14 (Table 2 ; Fig. 3 ). 15
16
Those decedents with confirmed Alzheimer's disease pathology (N = 255) showed similar 17 patterns of longitudinal changes in both scaling exponents, i.e., α 1 and α 2 declined over time at 18 the NCI stage, the decline accelerated after MCI onset, and further accelerated after the diagnosis 19 of dementia (Table 3 ; Fig. 3) . To explore the possible differences in FR degradation between this 20 subset and the other subjects in the cohort, we first performed additional linear mixed-effects 21 models using the remained subset (i.e., full cohort excluding 255 autopsy-confirmed Alzheimer's 22 disease subjects). Based on the estimated decline rates and standard errors at the three different 23 stages obtained from the two subsets, we calculated the t static and double-sided p values with 1 the assumption of independence and unequal variances between the two subsets. The results 2 suggested a significant group difference in the rate of α 1 decline at Alzheimer's dementia stage 3 (α 1 declined faster in deceased subjects with autopsy confirmed Alzheimer's pathology; p = 4 0.04). Besides, α 2 in the decedents with Alzheimer's pathology also declined significantly faster 5 than that in the remained subset at Alzheimer's dementia stage (p = 0.002). In addition, the 6 decline rates of α 1 at NCI and MCI stages in the decedents with Alzheimer's pathology were also 7 higher than those in the remained subset but the differences did not reach a statistical 8 significance (p = 0.07 at NCI stage; p = 0.09 at MCI stage). No significant group differences 9
were observed in the rates of α 2 decline at NCI and MCI stages (both p's > 0.2). 10
11
In addition, we also repeated these analyses using α 1 and α 2 obtained from motor activity 12 segments during the common active time (i.e., 10AM-9PM). The above observations persisted. 13
Specifically, (1) during the NCI stage, both α 1 and α 2 decreased over time with an annual decline 14 of 0.002 ± 0.0005 for α 1 (p < 0.0001) and of 0.003 ± 0.0007 for α 2 (p < 0.0001). (2) After MCI 15 diagnosis, α 1 declined much faster and the decline rate was increased by 150% (Estimate of 16 increase: 0.003 ± 0.0009; p = 0.0006). Similarly, α 2 also declined faster after MCI diagnosis, i.e., 17 the rate increased by ~167% after the diagnosis (Estimate of increase: 0.005 ± 0.002, p = 0.002). 18 (3) After the clinical onset of Alzheimer's disease, the declines in α 1 and α 2 were further 19 accelerated with an increase of 0.018 ± 0.003 for α 1 (3.6 times of the rate at MCI, p < 0.0001) 20
and an increase of 0.013 ± 0.005 for α 2 (1.6 times of the rate at MCI, p = 0.01), respectively. 21
The bivariate linear mixed models confirmed the gradual decreases in both α 1 and α 2 with time 1 (both p's < 0.0001), and gradual decline with time in global cognition (p < 0.0001 in both 2 models). In addition, the longitudinal change in global cognition was positively correlated with 3 the longitudinal changes in α 1 (correlation = 0.23, p = 0.0009) and in α 2 (correlation = 0.37, p < 4 0.0001) ( Table 4 ). Subsequent sensitivity analysis within 255 decedents with Alzheimer's 5 disease pathology at autopsy further confirmed these observations (Table 5) . 6 7 8
Discussion 9
Using a longitudinal, community-based cohort of over 1,000 participants, we have documented, 10 for the first time, the longitudinal degradation of FR in human motor activity for up to 13 years 11 during the progression of Alzheimer's disease. Specifically, FR was progressively degraded over 12 time, leading to more random fluctuations in motor activity over a range of time scales from ~5 13 minutes to up to 8 hours. Moreover, with the progression of Alzheimer's disease, we observed 14 much faster degradation of FR over time after the diagnosis of MCI (i.e., 2.50 times faster for α 1 15 and 2.33 time faster for α 2 ), and further after the diagnosis of Alzheimer's dementia (i.e., 4.40 16 times faster for α 1 and 2.10 time faster for α 2 ). Furthermore, we also found that the longitudinal 17 change of FR was strongly associated with decline of cognitive function throughout the disease 18 progression during different clinical stages from NCI to MCI and to Alzheimer's dementia. 19
Importantly, we confirmed the same effects in a portion of participants who had Alzheimer's 20 disease confirmed at autopsy. 21 predict the risk for dementia in the elders (Li et al., 2018) . Consistently, the current study showed 2 a longitudinal association between α 1 and cognition during the progression of Alzheimer's 3 disease. However, it is yet to be determined what neural nodes are responsible for the scaling 4 behavior at small time scales. To fill the knowledge gap, follow-up studies should be designed to 5 examine how fractal degradations are associated with neuropathologic changes in different brain 6 region using brain imaging data and/or postmortem brain histopathologic data. 7 8
Fractal patterns and rhythmicity 9
It is important to note that fractal and rhythmicity are distinguished properties of temporal 10 fluctuations. Changing one rhythm at a specific time scale may not affect fractal patterns. For 11 instance, our simulation study demonstrated that artificially induced 24-hour rhythmicity to 12 motor activity almost had no identifiable effects on fractal activity patterns [see involving in fractal regulation is basic rest-activity cycle (BRAC) or ultradian rhythm (Kleitman, 20 1963) . Since the observation of the 90-min sleep-stage cycle, ultradian rhythms between 2-6 21 hours have been identified in many neurophysiological processes including behavior and 22 hormone secretion even during wakefulness (Kleitman, 1982; Prendergast and Zucker, 2016) . 23
Though the neural circuitry of ultradian rhythmicity is still elusive, it is believed that ultradian 1 rhythms are integrated with circadian rhythm (Bourguignon and Storch, 2017). Based on the 2 theory of fractal physiology, it is tempting to speculate that the ultradian-circadian interaction is 3 one of the possible mechanisms generating fractal patterns in motor activity fluctuations from ~2 4 hours up to 24 hours. Further studies are warranted to test this speculation and to illustrate its 5 relevance to neurodegenerative progression in Alzheimer's disease. 6 7 Besides, another advantage of the scaling analysis over traditional rhythmicity or moments 8 approaches is that the scaling behavior seems more resilient to many direct masking effects on 9 actigraphy from such as housing, nursing home schedules for feeding and sleep, and interactions 10 between patients and caregivers (Hu et al., 2004). In a previous study, we also showed that 11 degraded fractal activity regulation in patients at late dementia can better predict neuron loss in 12 the suprachiasmatic nucleus than the combined predictive power of 3 rhythmicity measures (i.e., aging effects on circadian and cognitive functionalities. In this cohort, the value of α 2 was much 13 smaller than α 1 even at baseline when all participants were still cognitively healthy. This may be 14 explained by the observed faster decline of α 2 as compared to α 1 (Fig. 2) Interestingly, the FR degradation at time scales < 1.5 hours speeded up at older ages even within 21 the NCI stage (i.e., annual decline of α 1 was faster at older ages). We have confirmed this 22 finding by performing a separate linear mixed-effects model in a subset of the cohort in which all 23 subjects stayed at the NCI stage throughout the study period (N = 478; magnitudes of effects are 1 equivalent to these reported in Table 2 at the NCI stage). Following this finding, one natural 2 question is whether the observed accelerations of α 1 decline after MCI diagnosis and after 3 Alzheimer's dementia onset were simply due to the nonlinear aging effect because MCI and 4
Alzheimer's dementia occurred at older ages. To address this, we estimated the increases in the 5 decline rate of α 1 at MCI and AD stages using the age effect within the NCI stage as the 
Degraded fractal activity regulation independent of nighttime behavior 18
Our observations persisted after excluding the motor activity segments during the common sleep 19 period, precluding the possibility that the degradations in FR were caused by differences in 20 behavioral patterns during sleep. Actually, the α's obtained using data during the common active 21 time (i.e., 10AM-9PM) were highly correlated to those calculated using the complete data (R 2 = 22 0.8 for α 1 and 0.3 for α 2 ). These results indicate that our observed fractal degradations in the older individuals do not simply reflect possible disruptions in nighttime sleep; more likely they 1 reflect altered behavioral patterns during daytime (i.e., more random motor activity patterns). 2 Specifically, it is possible that alterations at small time scales (i.e., α 1 at < 1.5 h) may be linked 3 to less complex voluntary activity as subjects become unable to perform their activities of daily 4 living, and that alterations at larger time scales may reflect the disturbances in the circadian and 5 sleep-wake cycles, leading to disrupted rest-active patterns (e.g., more sleepiness and inactive 6 periods during daytime). 7 8 We note that it is possible that the scaling patterns of motor activity fluctuations during the night 9 may provide independent information. However, performing the proposed the scaling analysis on 10 data only during night time requires special caution due to a technical concern related to the 11 nature of the analysis and the sensitivity of accelerometer sensor equipped in the device. 12
Specifically, scaling/fractal analysis examines the temporal fluctuations (i.e., its amplitude and 13 structure) such that reliable results crucially depend on the signal to noise ratio. During the night 14 time, motor activity levels are normally very low for subjects with normal sleep and circadian 15 rhythms. In addition, with a limited sensitivity of the accelerometer sensors and the current 16 algorithm of filtering random background noise in actigraphy, the signal to noise ratio is quite 17 low during the night time. As a result, the results of DFA may be not reliable when using only 18 night time data. Thus, addressing this technical concern is necessary before the scaling behavior 19 of activity patterns during the night time can be applied in research and clinical studies. plausible that the effect of aging or Alzheimer's progression on α 2 starts earlier and is more 16 pronounced than that on α 1 , indicating that their influence on the circadian system might occur 17 earlier or is stronger than that on other control system(s) that contribute to α 1 . To formally 18 confirm/refute these possibilities, further studies are required to examine whether improving or 19 maintaining FR can prevent the development of AD or slow down the progression of the disease. 20
Study limitations
One limitation of this study is that the progression of Alzheimer's disease was estimated based 1 on its clinical symptoms (i.e., MCI and Alzheimer's dementia). To ensure that the FR 2 degradations observed in the cohort represented those in subjects with Alzheimer's pathology, 3 we analyzed a small subset of subjects who died and had pathologically confirmed Alzheimer's 4 disease at autopsy. We found similar degradation pattern of FR in these patients with slightly 5 larger effect sizes of aging as compared to the other subjects (e.g., both α 1 and α 2 declined faster 6 after dementia onset in autopsy-confirmed Alzheimer's disease patients). These results support 7 that the neuropathological process of Alzheimer's disease may underlie FR degradation and its 8 accelerations over time. Because ante-mortem Alzheimer's pathology biomarkers were not 9 available, many participants might have already Alzheimer's pathology even during the NCI 10 stage (but not confirmed with postmortem examinations yet) such that the observed fractal 11 degradation should be the combined effect of normal aging and Alzheimer's pathology. Thus, it 12 is highly possible that the aging effect was overestimated while the effect of Alzheimer's 13 dementia progression was underestimated. This may contribute to non-significant differences in 14 the decline rate of α 2 (at NCI and MCI stages) between those confirmed with Alzheimer's Dubois, B., Hampel, H., Feldman, H.H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., 4
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